Baicalin and Baicalein Enhance Cytotoxicity, Proapoptotic Activity, and Genotoxicity of Doxorubicin and Docetaxel in MCF-7 Breast Cancer Cells.

Joanna Bernasinska-Slomczewska, Pawel Hikisz, Anna Pieniazek, Aneta Koceva-Chyla
Author Information
  1. Joanna Bernasinska-Slomczewska: Department of Oncobiology and Epigenetics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143 Str., 90-236 Lodz, Poland. ORCID
  2. Pawel Hikisz: Department of Oncobiology and Epigenetics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143 Str., 90-236 Lodz, Poland.
  3. Anna Pieniazek: Department of Oncobiology and Epigenetics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143 Str., 90-236 Lodz, Poland. ORCID
  4. Aneta Koceva-Chyla: Department of Medical Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143 Str., 90-236 Lodz, Poland.

Abstract

Breast cancer is a major health concern and the leading cause of death among women worldwide. Standard treatment often involves surgery, radiotherapy, and chemotherapy, but these come with side effects and limitations. Researchers are exploring natural compounds like baicalin and baicalein, derived from the plant, as potential complementary therapies. This study investigated the effects of baicalin and baicalein on the cytotoxic, proapoptotic, and genotoxic activity of doxorubicin and docetaxel, commonly used chemotherapeutic drugs for breast cancer. The analysis included breast cancer cells (MCF-7) and human endothelial cells (HUVEC-ST), to assess potential effects on healthy tissues. We have found that baicalin and baicalein demonstrated cytotoxicity towards both cell lines, with more potent effects observed in baicalein. Both flavonoids, baicalin (167 µmol/L) and baicalein (95 µmol/L), synergistically enhanced the cytotoxic, proapoptotic, and genotoxic activity of doxorubicin and docetaxel in breast cancer cells. In comparison, their effects on endothelial cells were mixed and depended on concentration and time. The results suggest that baicalin and baicalein might be promising complementary agents to improve the efficacy of doxorubicin and docetaxel anticancer activity. However, further research is needed to validate their safety and efficacy in clinical trials.

Keywords

References

  1. Phytomedicine. 2010 Jan;17(1):63-8 [PMID: 19836937]
  2. Phytother Res. 2015 Dec;29(12):1987-90 [PMID: 26400418]
  3. Breast Care (Basel). 2013 Mar;8(1):60-6 [PMID: 24715845]
  4. J Bone Oncol. 2022 Feb 01;33:100415 [PMID: 35573641]
  5. J Ethnopharmacol. 2010 Mar 24;128(2):279-313 [PMID: 20064593]
  6. Sci Bull (Beijing). 2016;61(18):1391-1398 [PMID: 27730005]
  7. Proc Natl Acad Sci U S A. 1983 Jul;80(13):4045-9 [PMID: 6191328]
  8. Clin Transl Med. 2021 Nov;11(11):e577 [PMID: 34841716]
  9. Pharmacol Ther. 1993 Nov;60(2):185-214 [PMID: 8022857]
  10. Adv Pharm Bull. 2017 Sep;7(3):339-348 [PMID: 29071215]
  11. Biochem Pharmacol. 1999 Apr 1;57(7):727-41 [PMID: 10075079]
  12. Biomed Pharmacother. 2017 Jun;90:677-685 [PMID: 28415048]
  13. Cardiovasc Res. 2011 Feb 1;89(2):426-35 [PMID: 20851810]
  14. Pharmacol Res. 2021 Feb;164:105387 [PMID: 33352232]
  15. Pharmacol Ther. 2002 Nov-Dec;96(2-3):67-202 [PMID: 12453566]
  16. Cancers (Basel). 2022 Apr 26;14(9): [PMID: 35565294]
  17. Iran J Basic Med Sci. 2022 Jan;25(1):14-26 [PMID: 35656442]
  18. J Adv Pract Oncol. 2020 Mar;11(2):135-136 [PMID: 33532112]
  19. Int J Cancer. 2003 Mar 10;104(1):121-9 [PMID: 12532428]
  20. Onco Targets Ther. 2019 Dec 09;12:10749-10761 [PMID: 31849483]
  21. J Cell Biochem. 2011 Oct;112(10):2873-81 [PMID: 21618589]
  22. Nutr Cancer. 1996;26(2):167-81 [PMID: 8875554]
  23. Aging (Albany NY). 2016 Apr;8(4):603-19 [PMID: 27019364]
  24. Tumour Biol. 2016 Feb;37(2):2387-94 [PMID: 26376998]
  25. Biomed Res Int. 2019 Aug 6;2019:2187306 [PMID: 31467874]
  26. Oncologist. 2004;9 Suppl 2:3-8 [PMID: 15161985]
  27. Biomed Pharmacother. 2021 Jun;138:111445 [PMID: 33711551]
  28. CA Cancer J Clin. 2021 May;71(3):209-249 [PMID: 33538338]
  29. J Pharm Pharmacol. 2013 Nov;65(11):1577-89 [PMID: 24102557]
  30. Arch Pharm Res. 2022 Aug;45(8):535-557 [PMID: 35908250]
  31. Front Pharmacol. 2024 Feb 05;15:1264418 [PMID: 38375035]
  32. Eur J Med Chem. 2017 Jan 27;126:844-852 [PMID: 27960146]
  33. J Clin Oncol. 2003 Mar 15;21(6):959-62 [PMID: 12637456]
  34. J Manag Care Spec Pharm. 2015 Oct;21(10):863-71 [PMID: 26402387]
  35. J Neurosci Methods. 1999 Oct 15;92(1-2):153-9 [PMID: 10595713]
  36. Life Sci. 2016 Jan 1;144:8-18 [PMID: 26606860]
  37. Int J Mol Sci. 2022 Sep 20;23(19): [PMID: 36232344]
  38. Int J Environ Res Public Health. 2021 Jan 24;18(3): [PMID: 33498883]
  39. Biochem Pharmacol. 2005 Feb 15;69(4):699-708 [PMID: 15670588]
  40. Med Chem Res. 2016 Aug;25(8):1515-1523 [PMID: 28008217]
  41. Cancer Lett. 1997 Jan 30;112(2):127-33 [PMID: 9066718]
  42. Pharmacol Rev. 2004 Jun;56(2):185-229 [PMID: 15169927]
  43. Oncotarget. 2017 Jan 3;8(1):883-899 [PMID: 27903990]
  44. Biomed Pharmacother. 2018 Feb;98:806-812 [PMID: 29571250]
  45. Pharmacol Rev. 2000 Dec;52(4):673-751 [PMID: 11121513]
  46. Life Sci. 2006 Mar 27;78(18):2116-30 [PMID: 16455109]
  47. J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Dec 5;812(1-2):277-90 [PMID: 15556504]
  48. Int J Cancer. 2003 Sep 10;106(4):559-565 [PMID: 12845652]
  49. Antioxidants (Basel). 2021 Sep 23;10(10): [PMID: 34679641]
  50. Exp Cell Res. 1988 Mar;175(1):184-91 [PMID: 3345800]
  51. Mol Aspects Med. 2023 Oct;93:101205 [PMID: 37515939]
  52. Oncol Rep. 2015 Apr;33(4):2077-85 [PMID: 25672442]
  53. Biochem Biophys Res Commun. 2022 Dec 31;637:1-8 [PMID: 36375245]
  54. Cancer Chemother Pharmacol. 2021 Nov;88(5):771-793 [PMID: 34510251]
  55. Oncol Lett. 2017 Apr;13(4):2799-2804 [PMID: 28454469]
  56. Front Pharmacol. 2020 Jun 17;11:879 [PMID: 32625089]
  57. Cancer Treat Rev. 2009 Feb;35(1):57-68 [PMID: 19004559]
  58. Cancer. 2020 May 15;126 Suppl 10:2365-2378 [PMID: 32348571]
  59. Biochem Cell Biol. 1997;75(4):337-49 [PMID: 9493956]
  60. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4 [PMID: 388439]
  61. Nutrition. 2022 Oct;102:111732 [PMID: 35816809]
  62. Mol Cell Biochem. 2023 Jul;478(7):1519-1531 [PMID: 36413334]
  63. Med Res Rev. 2002 Sep;22(5):512-29 [PMID: 12210557]
  64. Int J Oncol. 2005 Jan;26(1):241-6 [PMID: 15586246]
  65. Nutr Cancer. 2009;61(3):310-21 [PMID: 19373604]
  66. Am J Chin Med. 2018;46(1):25-54 [PMID: 29316796]
  67. Rev Cardiovasc Med. 2022 Feb 22;23(2):73 [PMID: 35229564]
  68. Mol Med Rep. 2018 Feb;17(2):3085-3091 [PMID: 29257294]
  69. J Biol Chem. 1951 Nov;193(1):265-75 [PMID: 14907713]
  70. Biochem Biophys Res Commun. 2020 Oct 20;531(3):320-327 [PMID: 32800561]

MeSH Term

Humans
Flavonoids
Flavanones
Docetaxel
Doxorubicin
MCF-7 Cells
Apoptosis
Breast Neoplasms
Female
DNA Damage
Drug Synergism
Antineoplastic Agents
Cell Survival
Human Umbilical Vein Endothelial Cells

Chemicals

baicalein
baicalin
Flavonoids
Flavanones
Docetaxel
Doxorubicin
Antineoplastic Agents